Illumina, Roche accused of infringing genetic testing patents
07-12-2020
BGI wins partial lifting of Illumina injunction
13-08-2020
Natera and Illumina settle litigation, agree mutual licence
14-05-2020
Sundry Photography / Shutterstock.com
Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Illumina, Grail, cancer detection, oncology, mergers and acquisitions, M&A, Jeff Bezos, Bill Gates
